Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
The majority of patients with relapsed/refractory multiple myeloma (RRMM) are being undertreated and are receiving carfilzomib (Kyprolis) at a lower dosage, according to research presented at the 60th American Society of Hematology Annual Meeting and Exposition.1
Since carfilzomib was approved in 2012 to treat RRMM, higher doses of the therapy have been studied. Since 2016, the dose has been optimized for patients to received 56 mg/m2 twice weekly (optimized dose-56 BIW) with dexamethasone, and the more recent A.R.R.O.W. study has shown that a once-weekly dose of 70 mg/m2 (70 QW) improves progression-free survival compared with the twice-weekly dose of 27 mg/m2 (27 BIW) that was approved.
Interim results of the phase 3 A.R.R.O.W. study were presented at the 2019 American Society of Clinical Oncology Annual Meeting and published in The Lancet Oncology.2
The authors used IQVIA’s Oncology Electronic Medical Records database to identify 1469 patients with MM who were diagnosed between January 1, 2010, and October 31, 2017, who received 3 or more doses of carfilzomib. They compared overall survival and time to next treatment (TTNT) among patients treated with 27 BIW with patients who received the optimized dose-56 BIW/70 QW.
Of the patients studied, 129 patients (8.8%) received either the optimized dose-56 BIW/70 QW and 1340 patients (91.2%) received 27 BIW. At 12 months, 90.3% of patients in the optimized dose-56 BIW/70 QW group were alive compared with 79.7% of patients in the 27 BIW group. Patients in the optimized dose-56 BIW/70 QW group also had a 64% lower risk of death than the 27 BIW group.
TTNT, which is a proxy for progression-free survival, was 17.5 months for the optimized dose-56 BIW/70 QW group, which was significantly longer than the 13.2 months for the 27 BIW group.
“Our findings suggest that these patient-relevant outcomes may be improved in a vast majority of RRMM patients currently under-treated with carfilzomib by optimizing the dose, taking into consideration patients’ comorbidities and ability to tolerate therapy,” the authors concluded.
References
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen